Interest in branded programs wanes

Interest in attending sponsored speaker programs in a traditional dinner program format is waning, says medical meetings producer Pri-Med. Across 37 Pri-Med events in 2010, nearly 8,000 physicians opted into at least one pharma-sponsored promotional speaker program, the firm said. A 2009 survey completed by physicians as they were leaving branded programs at 12 meetings suggested higher numbers.
Who's the typical clinician sitting in on these events? According to a 2010 study of 2,238 speaker program attendees, there were only slight demographic differences between those clinicians who opted into sponsored speaker programs and those who did not.
Program attendees skewed slightly more toward hospital-based or hospital-owned practices. In addition, many were active and “high value” to industry (read: high-prescribing).
It's well known that more office practices are putting up barriers to sales reps. Nearly one in three physicians is hard to reach, Pri-Med says, meaning they are either heavily restrictive or don't see reps at all.
Away from their practices, though, it's a different story. Pri-Med found that physicians who are most restrictive regarding while in practice, often do opt in to branded speaker programs when already at an event where these promotional programs are available: three-quarters of “restricted” physicians and 58% of “no-see” physicians attended at least one promotional program.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.